Daniel A. Macuga Sells 5,751 Shares of USANA Health Sciences, Inc. (USNA) Stock
USANA Health Sciences, Inc. (NYSE:USNA) insider Daniel A. Macuga sold 5,751 shares of USANA Health Sciences stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $60.00, for a total value of $345,060.00. Following the sale, the insider now directly owns 2,077 shares in the company, valued at approximately $124,620. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of USANA Health Sciences, Inc. (NYSE USNA) opened at 59.45 on Thursday. The company has a market cap of $1.45 billion, a PE ratio of 15.44 and a beta of 1.10. USANA Health Sciences, Inc. has a 12-month low of $52.55 and a 12-month high of $75.00. The stock’s 50 day moving average price is $59.52 and its 200-day moving average price is $60.19.
USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 25th. The company reported $0.98 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.08. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The business had revenue of $257.10 million for the quarter, compared to the consensus estimate of $273.61 million. During the same period in the previous year, the firm earned $2.07 earnings per share. The company’s revenue was down .5% compared to the same quarter last year. On average, equities research analysts forecast that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current year.
USANA Health Sciences announced that its board has authorized a share buyback program on Tuesday, July 25th that allows the company to buyback $64.60 million in outstanding shares. This buyback authorization allows the company to purchase up to 46% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/31/daniel-a-macuga-sells-5751-shares-of-usana-health-sciences-inc-usna-stock.html.
A number of large investors have recently bought and sold shares of USNA. Renaissance Technologies LLC raised its stake in USANA Health Sciences by 10.6% in the second quarter. Renaissance Technologies LLC now owns 1,948,266 shares of the company’s stock worth $124,884,000 after buying an additional 186,600 shares during the last quarter. FMR LLC raised its stake in USANA Health Sciences by 3.9% in the second quarter. FMR LLC now owns 1,598,143 shares of the company’s stock worth $102,441,000 after buying an additional 60,033 shares during the last quarter. Vanguard Group Inc. raised its stake in USANA Health Sciences by 2.6% in the second quarter. Vanguard Group Inc. now owns 979,726 shares of the company’s stock worth $62,801,000 after buying an additional 25,136 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in USANA Health Sciences by 2.3% in the second quarter. Dimensional Fund Advisors LP now owns 710,918 shares of the company’s stock worth $45,570,000 after buying an additional 15,748 shares during the last quarter. Finally, Schroder Investment Management Group raised its stake in USANA Health Sciences by 9.0% in the second quarter. Schroder Investment Management Group now owns 572,186 shares of the company’s stock worth $36,734,000 after buying an additional 47,448 shares during the last quarter. 44.73% of the stock is currently owned by hedge funds and other institutional investors.
USNA has been the topic of a number of recent analyst reports. BidaskClub raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, June 13th. Pivotal Research raised USANA Health Sciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $55.00 to $75.00 in a report on Wednesday, May 3rd.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.